Rivaroxaban Versus Aspirin for Secondary Prevention o
With Cancer: A Subgroup Analysis of the NAVIGATE ES

European Journal of Neurology

27, 841-848

DOI: 10.1111/ene.14172

Citation Report

#	Article	IF	Citations
1	It's Time to Say Goodbye to the ESUS Construct. Frontiers in Neurology, 2020, 11, 544650.	3.5	26
2	Suitability of Thrombolysis for Patients With Acute Ischemic Stroke Complicated With Trousseau Syndrome. Frontiers in Neuroscience, 2020, 14, 504521.	4.2	3
3	How I Treat Unexplained Arterial Thrombosis. Blood, 2020, 136, 1487-1498.	10.6	35
4	Cancer and Embolic Stroke of Undetermined Source. Stroke, 2021, 52, 1121-1130.	9.1	162
5	Современные алгоритмы диагностики и лечения транзиторных ишемических атак. Klinicheskaia Meditsina, 2021, 99, 85-90.	0.3	1
6	Therapeutic Efficacy of Heparin and Direct Factor Xa Inhibitors in Cancer-Associated Cryptogenic Ischemic Stroke With Venous Thromboembolism. Thrombosis Research, 2021, 206, 99-103.	2.9	17
7	Cardiovascular Magnetic Resonance Imaging and Its Role in the Investigation of Stroke: An Update. Journal of Neurology, 2021, 268, 2597-2604.	5.4	6
8	Een ischemische beroerte als presentatie van een occulte maligniteit: typisch beeld op een MRI van de hersenen. Tijdschrift Voor Geneeskunde, 2021, .	0.0	0
9	A Critical Assessment of the Current Pharmacotherapy for the Treatment of Embolic Strokes of Undetermined Source. Expert Opinion on Pharmacotherapy, 2022, 23, 905-915.	3.5	4
10	Review and Update of the Concept of Embolic Stroke of Undetermined Source. Nature Reviews Neurology, 2022, 18, 455-465.	35.8	109
11	Cancer and Stroke: Commonly Encountered by Clinicians, but Little Evidence to Guide Clinical Approach. Therapeutic Advances in Neurological Disorders, 2022, 15, 17562864221106362.	4.0	34
12	Cancer-Related Stroke: Exploring Personalized Therapy Strategies. Brain and Behavior, 2022, 12, e2738.	3.1	21
13	Short-Term Outcomes in Patients With Lung Cancer-Associated Acute Ischemic Stroke. Thoracic Cancer, 2022, 13, 2751-2758.	2.9	3
14	Cancer and Stroke: What Do We Know and Where Do We Go?. Thrombosis Research, 2022, 219, 133-140.	2.9	31
15	Embolic Stroke of Undetermined Source: Current Perspectives on Diagnosis, Investigations, and Management. Canadian Journal of Cardiology, 2023, 39, 172-186.	3.8	5
16	Ischemic Stroke in Patients With Malignancy. Mayo Clinic Proceedings, 2022, 97, 2139-2144.	3.7	23
17	Cardiovascular Outcomes and Mortality After Incident Ischaemic Stroke in Patients With a Recent Cancer History. European Journal of Internal Medicine, 2023, 109, 50-57.	4.2	5
18	Effect of the Frequency of Rehabilitation Treatments on the Long-Term Mortality of Stroke Survivors With Mild-to-Moderate Disabilities Under the Korean National Health Insurance Service System. Healthcare, 2023, 11, 1587.	4.1	3

#	Article	IF	Citations
19	Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients: Systematic Review and Meta-Analysis. Cardio-Oncology, 2023, 5, 520-532.	5.3	21
20	Cryptogenic Stroke. Part 4: Antiphospholipid Syndrome and Cancer. Meditsinskiy Sovet, 2023, .	0.4	1
21	Ischemic Stroke in Cancer: Mechanisms, Biomarkers, and Implications for Treatment. Seminars in Thrombosis and Hemostasis, 2024, 50, 342-359.	4.1	27
22	Clinical Analysis of Twenty-One Cases of Acute Ischemic Stroke Related to Trousseau Syndrome. Neurological Sciences, 2024, 45, 1537-1547.	2.4	5
23	Non-Hypertensives and Those With Normal Cholesterol Are More Likely to Have Concomitant Cancer Amongst Patients With Ischemic Stroke: A Retrospective Cross-Sectional Registry-Based Study. Cerebrovascular Diseases Extra, 2023, 13, 75-82.	1.8	2
24	Cancer-Related Arterial Thromboembolic Events. Archives of Cardiovascular Diseases, 2024, 117, 101-113.	2.5	21
25	Acute Ischaemic Stroke in Active Cancer Versus Non-Cancer Patients: Stroke Characteristics, Mechanisms and Clinical Outcomes. European Journal of Neurology, 2024, 31, e16200.	4.4	10
26	Cancer and Arterial Thrombosis: Therapeutic Options. Research and Practice in Thrombosis and Haemostasis, 2024, 8, 102393.	3.3	11
27	Malignancy-Associated Ischemic Stroke: Implications for Diagnostic and Therapeutic Workup. CNS Neuroscience and Therapeutics, 2024, 30, e14619.	6.5	5
28	Cancer-Associated Ischemic Stroke: Current Knowledge and Future Directions. Bleeding, Thrombosis, and Vascular Biology, 2024, .	0.3	6
29	Arterial Thrombosis in Patients With Cancer. Cancers, 2024, 16, 2238.	5.3	13
30	Cancer-Associated Stroke: Thrombosis Mechanism, Diagnosis, Outcome, and Therapeutic Strategies. Journal of Stroke, 2024, 26, 164-178.	7.6	49
31	Traduction et republication de : « Événements thromboemboliques artériels liés au cancer ». Revue De Medecine Interne, 2024, 45, 498-511.	0.5	0
32	Diagnosis of Incident Cancer After Cryptogenic StrokeAn Exploratory Analysis of the ARCADIA Randomized Trial. Neurology, 2024, 103, e210027.	5.0	2
33	Epidemiology, Pathophysiology, and Management of Cancer-Associated Ischemic Stroke. Cancers, 2024, 16, 4016.	5.3	7
34	Hidden Cancer as the Cause of an Ischemic Stroke: A Case Report. Cureus, 2025, 17, e82001.	1.3	0
35	Effectiveness and Safety of Dual Antiplatelet Therapy in Patients With Minor Ischemic Stroke or Transient Ischemic Attack and Cancer: A Secondary Analysis of the READAPT Study. European Stroke Journal, 2025, 10, 1489-1501.	5.8	0
36	Integrated Management of Stroke Risk in Brain Cancer: Insights From the Tumoral Bleeding Classification System and CanStroke Protocol. Journal of Stroke Medicine, 2025, 8, 22-45.	0.4	2

#	Article	IF	Citations
37	Antithrombotic Therapy for Secondary Stroke Prevention in Patients With Cancer: A Systematic Review and Network Meta-Analysis. European Journal of Clinical Pharmacology, 2025, 81, 1001-1015.	3.8	2
38	Cryptogenic Embolic Stroke and Cancer. Frontiers in Neurology, 2025, 16, 1537779.	3.5	5
39	Cerebrovascular and Peripheral Vascular Complications in Cancer Patients. Current Neurology and Neuroscience Reports, 2025, 25, 46.	8.7	5
40	Outcomes of Patients With Embolic Stroke of Undetermined Source Treated With Antiplatelet Agents or Anticoagulation. Neurology, 2025, 105, e213876.	5.0	10
41	Editorial: Cryptogenic Ischemic Stroke. Frontiers in Neurology, 2025, 16, 1692475.	3.5	0
42	Anticoagulant Versus Antiplatelet Treatment for Secondary Stroke Prevention in Patients With Active Cancer. Frontiers in Neurology, 2025, 16, 1530775.	3.5	4
43	Proposal for the Ischemic Stroke Phenotyping System 2025: ISPS25. Stroke, 2025, 56, 3552-3562.	9.1	8
44	Hard Times for Anticoagulation in Cancer-Associated Stroke. Neurology, 2025, 105, e214395.	5.0	4
45	Anticoagulant Usage and Risk of Thromboembolic Events After Ischemic Stroke in Adults With Cancer. Neurology, 2025, 105, e214325.	5.0	6
46	Comparison of Antiplatelets and Anticoagulants for Secondary Stroke Prevention in Ischemic Stroke Patients With Cancer: A Meta-Analysis. Journal of Innovative Optical Health Sciences, 2026, 21, 038-045.	1.2	1
47	Home Intravenous Heparin Therapy via a Central Venous Port for Recurrent Cancer-Associated Stroke Requiring Repeat Mechanical Thrombectomy: A Case Report. Internal Medicine, 2026, 65, 6405-25.	1.1	1
48	Observational Study Examines Use of Anticoagulants in Patients With Stroke and Cancer. Neurology Today: an Official Publication of the American Academy of Neurology, 2026, 26, 15-17.	0.0	0
49	Development and Validation of the Predicting Risk of Ischemic Stroke in Malignancy Estimation Tool. Journal of the American Heart Association, 2026, 15, e045631.	5.8	2
50	Classification and Management of Ischemic Stroke in Patients With Active Cancer: A Scientific Statement From the American Heart Association. Stroke, 2026, 57, e160-e173.	9.1	16
51	Antithrombotic Agents for Secondary Ischemic Stroke Prevention in Cancer Patients With Atrial Fibrillation: A Tertiary Medical Center Retrospective Study. Medicine (United States), 2026, 105, e47883.	2.1	0
52	Understanding Clot Composition in Cancer-Associated Thromboembolism. Journal of Cerebral Blood Flow and Metabolism, 2026, 46, 1996-2011.	5.6	0
53	Arterial Thromboembolism. , 2026, .		0
54	A Bibliometric Analysis of Cardioembolic Stroke Utilizing HistCite Pro, CiteSpace, and VOSviewer. Medicine (United States), 2026, 105, e49247.	2.1	0

#	Article	IF	Citations
55	Antithrombotic Use Patterns for Secondary Stroke Prevention in Ischemic Stroke Patients With Active Malignancy: The STOP-SPAM Study. Journal of the Neurological Sciences, 2026, 491, 126173.	2.7	0
56	Anticoagulation Treatment Response Among Phenotypic ESUS Clusters: Evidence From CASPR. Annals of Clinical and Translational Neurology, 2026, .	4.3	0